

## **Analysis of the assortment of chondroprotective drugs in pharmacies**

**Podkolzina M.V., Lebedyn A.M., Kurylenko Y.E.**

*Department of Organization and Economy of Pharmacy*

*National University of Pharmacy, c. Kharkiv, Ukraine*

alla\_leb7@ukr.net

**Introduction.** Diseases of the musculoskeletal system are one of the causes of disability and disability of the population, cause a deterioration in the quality of life and entail significant financial costs for treatment. According to the World Health Organization (WHO), about 4% of the world's population suffer from osteoarthritis, in 10% of cases it is this disease that causes disability.

According to the international statistical classification of diseases and health problems of the 10th revision (ICD-10), the terms: “osteoarthrosis”, “arthrosis”, “osteoarthritis” are synonyms and differ only in local classifications depending on the country where they are used. The term “osteoarthritis” is most often used in Ukraine; in the countries of Europe and the USA, “osteoarthrosis”. Osteoarthrosis (OA) – one of the most common degenerative-dystrophic diseases.

In Ukraine, OA is the most common joint disease. According to official statistics, in 2015 the number of newly registered cases of diseases of the musculoskeletal system and connective tissue was 2919 cases per 100 thousand people, the incidence rate was 1245523 people, which is 4,65% of the total number of diseases. Today, the prevalence of OA in Ukraine is 2200.6 cases per 100 thousand people, i.e., there is a tendency to a decrease in the incidence of [1].

**Materials and methods.** The system analysis was used in the work, including methods of statistical, structural, graphical and marketing analysis. Data from the State Register of Medicines, research companies and manufacturing enterprises, as well as medical statistics.

**Results.** According to the Institute for Strategic Studies of the Ministry of Health of Ukraine in 2016, the share of bone fractures among all traumatic injuries was 86.4%, which equals 3.5 thousand patients per 100 thousand population. The number of patients who lose their working capacity has reached 1.58 million people (or 3.6% of the total population of Ukraine). Most of the fractures provoke diseases of the musculoskeletal system.

Given the projected increase in life expectancy in the coming years, there will be an increase in cases of osteoporotic fractures. Therefore, by 2035, in men the number of cases of fractures of the proximal femur is projected to grow by 36%, in women – by 43% [3].

Complex therapy of diseases of the musculoskeletal system is not complete without drugs chondroprotective action. To date, the pharmaceutical market of Ukraine has a fairly wide range of medicines of chondroprotective action of domestic and imported production [1, 4].

Depending on the speed of action, the drugs used to treat OAA diseases are divided into fast-acting and slow-acting ones. SYSADOA – (Symptomat Slow Acting Drugs for OsteoArthritis) – symptomatic slow-acting drugs (glucosamine, chondroitin sulfate, diacerein, hyaluronic acid) – exhibit a symptomatic effect and low toxicity. In clinical practice, preference is given to the appointment of combination drugs.

Because of the analysis of the assortment of medicines (drugs) of chondroprotective action, it was established that 40 trade names of drugs are represented on the pharmaceutical market of Ukraine. The main share of chondroprotective drugs on the Ukrainian market belongs to the imported manufacturer (52.5%), domestic drugs occupy 47.5%. In general, the nomenclature of Ukrainian drugs is provided by six manufacturing companies. The leaders are three pharmaceutical companies that produce five drugs each (12.5% each) pharmaceutical company (PC): Zdorovie, Kharkov, Fitofarm, Artyomovsk, Donetsk Region, Farmak, Kiev [2].

An analysis of the assortment of chondroprotective drugs showed that the largest share was made up of combined drugs containing a combination of chondroitin sulfate and glucosamine – 35%. Monopreparations of the M01AX25 group Chondroitin sulfate – 27.5%, M01AX05 Glucosamine – 17.5%. Of the 40 trade names, drugs are most produced: in the form of tablets coated with a coating of 12 drugs (30%), in the form of solutions for injection – 11 names of drugs (27.5%), in the form of capsules – 7 (17.5%), soft dosage forms – 6 drugs (15%), powders for oral administration – (10%).

**Conclusions.** Diseases of the musculoskeletal system is one of the main causes of disability and disability. These diseases cause a deterioration in the quality of life and entail significant financial costs for treatment. Analysis of the assortment of chondroprotectors showed that most of the drugs are presented in the form of coated tablets (30%) and injection solutions (27.5%). At the same time, most of the drugs (52.5%) are imported. An analysis of the assortment of chondroprotective drugs showed that the largest share was made up of combined drugs containing a combination of chondroitin sulfate and glucosamine – 35%. Monopreparations of the M01AX25 group Chondroitin sulfate – 27.5%, M01AX05 Glucosamine – 17.5%.

#### **References:**

1. Алексеева Л.И. Хондроитин сульфат в лечении остеоартроза // Новости медицины и фармации. – 2008. – №15 (252). – С. 23-25.
2. Державний реєстр лікарських засобів України [Електронний ресурс]. – Режим доступу: <http://www.drlz.kiev.ua/>
3. Князькова И. И. Лечение остеоартроза / И. И. Князькова // Здоров'я України. – 2016. – № 2. – С. 56-58.
4. Bruyere O., Burlet N., Delmas P. et al. Evaluation of Symptomatic Slow-Acting Drugs in Osteoarthritis Using the GRADE System. BMC Musculoskelet Dis 2008; 16(9) : 165.